In January, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) recommended approving the drug Kesimpta with the active agent ofatumumab, and now, this has led to a European marketing authorization from the EU Commission, according to a press statement from Genmab.
The commission gave this authorization to Swiss pharmaceutical giant Novartis, who has collaborated with Genmab on Kesimpta, which will be the first EU-approved drug treating adults with relapsing multiple sclerosis, which patients can administer themselves.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
US government exercises option to buy Bavarian smallpox vaccines for USD 119m
The first option in an existing contract with the US has been utilized, and Bavarian Nordic can start manufacturing freeze-dried doses of Jynneos for the country in 2023.
Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug
The Danish Medicines Agency has reported that it is currently difficult to find diabetes drug Novorapid in Denmark.
Procurement Manager, Direct Materials 
IRT Manager, Clinical Drug Supply 
2 Sales Representatives and Product Specialists 
Quality System Manager 
Cell Culture Scientist/Senior Scientist 
Key Account Manager, Europe and Asia 
Clinical Project Manager 
Vice President, Test & Characterisation 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Project Manager & Scrum Master 
Procurement Process Excellence Specialist 
CMO Operations Specialist - screening & selection of CMO/CDMO’s